Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Cost of Revenue (2017 - 2025)

Historic Cost of Revenue for Neurocrine Biosciences (NBIX) over the last 8 years, with Q4 2025 value amounting to $17.6 million.

  • Neurocrine Biosciences' Cost of Revenue rose 8924.73% to $17.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $52.1 million, marking a year-over-year increase of 5323.53%. This contributed to the annual value of $52.1 million for FY2025, which is 5323.53% up from last year.
  • According to the latest figures from Q4 2025, Neurocrine Biosciences' Cost of Revenue is $17.6 million, which was up 8924.73% from $14.0 million recorded in Q3 2025.
  • In the past 5 years, Neurocrine Biosciences' Cost of Revenue ranged from a high of $17.6 million in Q4 2025 and a low of $2.9 million during Q1 2021
  • Moreover, its 4-year median value for Cost of Revenue was $9.2 million (2024), whereas its average is $9.1 million.
  • Per our database at Business Quant, Neurocrine Biosciences' Cost of Revenue tumbled by 2857.14% in 2024 and then skyrocketed by 8924.73% in 2025.
  • Neurocrine Biosciences' Cost of Revenue (Quarter) stood at $4.2 million in 2021, then soared by 102.38% to $8.5 million in 2023, then rose by 9.41% to $9.3 million in 2024, then surged by 89.25% to $17.6 million in 2025.
  • Its Cost of Revenue stands at $17.6 million for Q4 2025, versus $14.0 million for Q3 2025 and $11.3 million for Q2 2025.